Which chemotherapy agent is most commonly associated with hypomagnesemia?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Prepare for the CPHON Chemotherapy Test with interactive materials. Use flashcards and multiple choice questions with hints and explanations. Get exam-ready!

Multiple Choice

Which chemotherapy agent is most commonly associated with hypomagnesemia?

Explanation:
Cisplatin is well known for causing nephrotoxicity, which leads to renal magnesium wasting and, consequently, hypomagnesemia. The drug damages kidney tubules, reducing magnesium reabsorption and causing it to be lost in the urine. This makes low magnesium a common electrolyte disturbance with cisplatin therapy. The other drugs have different primary toxicities—mitoxantrone is more associated with myelosuppression and cardiotoxicity, cyclophosphamide with hemorrhagic cystitis and bone marrow suppression, and vincristine with neurotoxicity—so they are not typically linked to hypomagnesemia.

Cisplatin is well known for causing nephrotoxicity, which leads to renal magnesium wasting and, consequently, hypomagnesemia. The drug damages kidney tubules, reducing magnesium reabsorption and causing it to be lost in the urine. This makes low magnesium a common electrolyte disturbance with cisplatin therapy. The other drugs have different primary toxicities—mitoxantrone is more associated with myelosuppression and cardiotoxicity, cyclophosphamide with hemorrhagic cystitis and bone marrow suppression, and vincristine with neurotoxicity—so they are not typically linked to hypomagnesemia.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy